Dark

Search

MNTA
Momenta Pharmaceuticals, Inc. Common Stock
stock NASDAQ

No price data

0.000.000%(0.00)0

Headquarters

MA, USA

Industry

Drug Manufacturers

Related

AMGN MDCO BIIB NVS BAX BMY JNJ PFE MRK TEVA XLV

Oct 1, 2020

08:45AM EDT Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, Momenta or the Company), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the successful completion of its sale to Johnson & Johnson for $52.50 per share, totaling approximately $6.5 billion. GlobeNewswire Inc

Sep 25, 2020

05:48PM EDT Chesapeake Utilities to Join S&P SmallCap 600 PR Newswire

Sep 17, 2020

04:31PM EDT ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders PR Newswire

Sep 16, 2020

02:32PM EDT Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Rosetta Stone Inc. (NYSE: RST), Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), Jernigan Capital, Inc. (NYSE: JCAP), and Varian Medical Systems, Inc. (NYSE: VAR). Additional information about each potential action can be found at the link provided. GlobeNewswire Inc

Sep 15, 2020

08:19AM EDT Momenta Pharmaceuticals Announces Expiration Of Hart-Scot-Rodino Waiting Period In Connection With Proposed Sale To Johnson & Johnson Benzinga

Profile

Momenta Pharmaceuticals Inc is a biotechnology company. It is engaged in developing generic versions of complex drugs, biosimilars and novel therapeutics for oncology and autoimmune disease.

Share